Saddled with a black box and low dose, Lilly, Incyte RA drug Olumiant faces uphill fight
admin 1st June 2018 Uncategorised 0The 2-mg dose of Eli Lilly and Incyte’s rheumatoid arthritis drug Olumiant picked up an FDA approval after independent experts flagged safety concerns on the 4-mg dose. And with a black-box warning on its label, the new med will face an uphill fight for sales.
More: Saddled with a black box and low dose, Lilly, Incyte RA drug Olumiant faces uphill fight
Source: fierce